La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

CONMED Croissance future

Future contrôle des critères 3/6

CONMED devrait augmenter ses bénéfices et son chiffre d'affaires de 23.8% et de 7% par an respectivement. Le BPA devrait croître de de 24% par an. Le rendement des capitaux propres devrait être 14.8% dans 3 ans.

Informations clés

23.8%

Taux de croissance des bénéfices

24.0%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.4%
Taux de croissance des recettes	7.0%
Rendement futur des capitaux propres	14.8%
Couverture par les analystes	Good
Dernière mise à jour	05 Aug 2024

Mises à jour récentes de la croissance future

US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results

Feb 03

Recent updates

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

Aug 15

CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price

Jul 17

CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%

Feb 15

US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results

Feb 03

Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?

Jan 08

Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects

Dec 18

CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt

Nov 30

Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business

Oct 28

Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?

Sep 22

Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?

Aug 24

Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly

Jul 28

Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?

Jun 08

These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively

May 17

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

Apr 28

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

Mar 10

Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden

Feb 14

CONMED Non-GAAP EPS of $0.42 misses by $0.48, revenue of $250.9M misses by $51.58M

Feb 02

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

Jan 24

ConMed: Still Fairly Priced, Turning More Constructive

Dec 09

At US$83.60, Is CONMED Corporation (NYSE:CNMD) Worth Looking At Closely?

Nov 18

Conmed withdraws FY22 guidance on software implementation-related disruption

Nov 15

CONMED (NYSE:CNMD) Has A Pretty Healthy Balance Sheet

Oct 11

ConMed: Fairly Priced At Pre-Pandemic Market Cap

Sep 21

CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20

Sep 03

CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20

Aug 18

CONMED declares $0.20 dividend

Aug 11

Prévisions de croissance des bénéfices et des revenus

NYSE:CNMD - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	1,512	175	196	192	6
12/31/2025	1,410	141	188	160	8
12/31/2024	1,308	108	137	130	8
6/30/2024	1,276	99	159	175	N/A
3/31/2024	1,262	82	142	158	N/A
12/31/2023	1,245	64	106	125	N/A
9/30/2023	1,169	58	38	57	N/A
6/30/2023	1,139	88	16	37	N/A
3/31/2023	1,099	-94	7	29	N/A
12/31/2022	1,045	-81	12	33	N/A
9/30/2022	1,069	-83	59	79	N/A
6/30/2022	1,042	-114	56	74	N/A
3/31/2022	1,020	68	74	90	N/A
12/31/2021	1,011	63	97	112	N/A
9/30/2021	989	62	83	98	N/A
6/30/2021	979	54	99	112	N/A
3/31/2021	881	13	70	83	N/A
12/31/2020	862	10	52	65	N/A
9/30/2020	874	0	69	85	N/A
6/30/2020	870	0	69	87	N/A
3/31/2020	951	34	84	103	N/A
12/31/2019	955	29	75	95	N/A
9/30/2019	933	29	60	79	N/A
6/30/2019	901	28	28	47	N/A
3/31/2019	876	31	29	46	N/A
12/31/2018	860	41	58	75	N/A
9/30/2018	840	72	55	71	N/A
6/30/2018	828	73	65	80	N/A
3/31/2018	812	71	N/A	75	N/A
12/31/2017	796	55	N/A	66	N/A
9/30/2017	778	15	N/A	58	N/A
6/30/2017	773	16	N/A	70	N/A
3/31/2017	769	12	N/A	72	N/A
12/31/2016	764	15	N/A	40	N/A
9/30/2016	750	16	N/A	36	N/A
6/30/2016	735	17	N/A	24	N/A
3/31/2016	722	22	N/A	17	N/A
12/31/2015	719	30	N/A	51	N/A
9/30/2015	723	34	N/A	64	N/A
6/30/2015	729	27	N/A	65	N/A
3/31/2015	736	30	N/A	63	N/A
12/31/2014	740	32	N/A	65	N/A
9/30/2014	747	31	N/A	67	N/A
6/30/2014	750	35	N/A	83	N/A
3/31/2014	753	34	N/A	93	N/A
12/31/2013	763	36	N/A	81	N/A
9/30/2013	756	37	N/A	88	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CNMD ( 23.8% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de CNMD ( 23.8% par an) devraient croître plus rapidement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de CNMD devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CNMD ( 7% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CNMD ( 7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de CNMD devrait être faible dans 3 ans ( 14.8 %).

CONMED Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates increase by 10%, revenue downgraded

Price target decreased by 8.8% to US$84.25

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results

CONMED Corporation Provides Financial Guidance for the Full Year 2024

Recent updates

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

Second quarter dividend of US$0.20 announced

Consensus EPS estimates increase by 10%, revenue downgraded

Price target decreased by 8.8% to US$84.25

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price

CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024

AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation

Insider notifies of intention to sell stock

Upcoming dividend of US$0.20 per share

There Is A Reason CONMED Corporation's (NYSE:CNMD) Price Is Undemanding

First quarter dividend of US$0.20 announced

CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024

Is CONMED (NYSE:CNMD) Using Too Much Debt?

Insider exercised options and sold US$721k worth of stock

Upcoming dividend of US$0.20 per share

CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024

CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%

US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results

Full year 2023 earnings: EPS misses analyst expectations

CONMED Corporation Provides Financial Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 17%

Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?

Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024

CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt

Consensus EPS estimates fall by 11%

Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business

Price target decreased by 9.5% to US$123

Third quarter 2023 earnings: EPS misses analyst expectations

CONMED Corporation Updates Third Quarter Guidance for 2023

CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023

Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?

Upcoming dividend of US$0.20 per share at 0.7% yield

Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly

CONMED Corporation Revises Earnings Guidance for the Full Year 2023

CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023

Insider notifies of intention to sell stock

Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?

Upcoming dividend of US$0.20 per share at 0.6% yield

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023

Insider notifies of intention to sell stock

These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively

Insider recently sold US$166k worth of stock

Price target increased by 13% to US$126

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman of the Board recently sold US$464k worth of stock

Executive VP & CFO exercised options and sold US$1.2m worth of stock

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

Upcoming dividend of US$0.20 per share at 0.8% yield

Special Counsel & Corporate Secretary exercised options and sold US$283k worth of stock

Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 11% to US$110

CONMED Corporation Provides Earnings Guidance for the Full Year 2023

CONMED Non-GAAP EPS of $0.42 misses by $0.48, revenue of $250.9M misses by $51.58M

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

CONMED Corporation to Report Q4, 2022 Results on Feb 02, 2023

Executive VP & CFO exercised options and sold US$174k worth of stock